14 Mar Diabetes: TNFR1 As Biomarker of Renal Disease and Mortality
MedicalResearch.com Interview with:
Prof Samy Hadjadj:
Université de Poitiers, UFR Médecine Pharmacie, Centre d’Investigation clinique,
CHU de Poitiers, Centre d’Investigation clinique, Poitiers, France
MedicalResearch.com: What are the main findings of the study?
Prof: Hadjadj: The study helps to establish sTNFR1 as a valid biomarker not only for renal outcomes in type 2 diabetes but also for all cause death. Interestingly the addition of sTNFR1 concentration to the UKPDS model outcome equation showed to add some clinical prognostic value to this model for all-cause death.
MedicalResearch.com: Were any of the findings unexpected?
Prof: Hadjadj: Not really. Our primary hypothesis was that a potent marker for renal disease in type 2 diabetes could well translate into a good biomarker for all cause death. It proved to be the case, studying our large-scale inception monocentric cohort of ca 500 Type 2 diabetes patients with diabetic kidney disease (DKD).
MedicalResearch.com: What should clinicians and patients take away from your report?
Prof: Hadjadj: Clinicians have improved their knowledge of new biomarker, that are relevant for risk of death (after careful analysis of the additional value of the marker on top of clinical and biological markers used in the UKPDS equation). This can clearly help to tailor the prognosis of these patients.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Prof: Hadjadj: We strongly believe that we should move forward studying non DKD type 2 diabetes patients. In addition whether the fine-tuning of prognosis helps to better tailor therapeutic interventions still needs to be studied.
Citation:
Last Updated on March 14, 2014 by Marie Benz MD FAAD